Clinical Trials Logo

Filter by:
NCT ID: NCT05302921 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Start date: February 18, 2022
Phase: Phase 2
Study type: Interventional

The is a phase II, single arm, open-label, multi-site trial studying the combination of cryoablation therapy and dual checkpoint inhibition with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) given at the recommended phase 2 dose (RP2D) in pediatric and young adult patients with relapsed or refractory solid tumors.

NCT ID: NCT05302596 Active, not recruiting - Obesity Clinical Trials

Semaglutide Use in Elderly Obese Patients

Start date: September 1, 2022
Phase: Phase 4
Study type: Interventional

This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly obese subjects on body weight and body composition as assessed by DEXA.

NCT ID: NCT05302050 Active, not recruiting - Diabetes Type 2 Clinical Trials

A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes Mellitus

ACTION-DM
Start date: March 7, 2022
Phase: N/A
Study type: Interventional

Randomized, controlled, pragmatic trial with open-label extension evaluating BT-001, an investigational digital therapeutic intended to help patients with type 2 diabetes improve their glycemic control.

NCT ID: NCT05301751 Active, not recruiting - Clinical trials for Diabetic Macular Edema

AG-73305 Single Ascending Dose Cohort Study in DME

Start date: June 9, 2022
Phase: Phase 2
Study type: Interventional

This is a multi-centered, open-labeled, single ascending-dose-cohort study to evaluate 4 dosing cohorts of AG-73305 administered by intravitreal injection in patients with diabetic macular edema (DME).

NCT ID: NCT05301036 Active, not recruiting - Clinical trials for Major Depressive Episode

Personalized Ultrasonic Brain Stimulation for Depression

Start date: July 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate a new form of non-invasive brain stimulation for individuals with depression. Personalized low-intensity transcranial focused ultrasound stimulation will first be delivered using a range of stimulation parameters during psychological and physiological monitoring. A well-tolerated stimulation protocol will then be selected for subsequent testing in a blinded randomized sham-controlled cross-over trial to evaluate brain target engagement using magnetic resonance imaging.

NCT ID: NCT05300048 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Start date: April 22, 2022
Phase: Phase 1
Study type: Interventional

This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.

NCT ID: NCT05299983 Active, not recruiting - Menopause Clinical Trials

MyMenoPlan: Online Resource for Improving Women's Menopause Knowledge and Informed Decision-making

Start date: January 15, 2022
Phase: N/A
Study type: Interventional

As part of a National Institute on Aging -funded R01, the investigators developed an evidence-based, multi-media digital resource entitled MyMenoPlan to help women learn about the menopause transition, and the symptoms and treatments of perimenopause/menopause. MyMenoPlan is also designed to help women learn about the effectiveness of treatments for a comprehensive list of midlife symptoms and compare treatments that may help with the specific symptoms women are experiencing.

NCT ID: NCT05299723 Active, not recruiting - Clinical trials for Acute Coronary Syndrome

The SleepWell Study - Chronotherapeutic Intervention to Improve Sleep Following ACS

Start date: April 18, 2022
Phase: N/A
Study type: Interventional

This two-phase pilot study will test the feasibility of a "combined chronotherapy" (CC) intervention consisting of morning bright light therapy (BLT) and evening blue light blocking (BLB), administered daily for 4 weeks in patients who experienced acute coronary syndrome (ACS). Phase A of the study will be a single-arm open-label study of the home-based CC intervention in 5 post-ACS patients. Phase B of the study will be a parallel-arm randomized clinical trial (RCT) in which 15 post-ACS patients will be randomized (using a 2:1 allocation) to active CC treatment or sleep hygiene education control group. In Phase A and Phase B, the primary aims are study feasibility, acceptability, appropriateness, and usability. In Phase B, the investigator will additionally assess whether the intervention engages its proposed proximal target mechanism - sleep.

NCT ID: NCT05299671 Active, not recruiting - Cancer Clinical Trials

Video Consultation to Reduce Drug Interactions Among Patients Initiating Oral Anti-Cancer Drugs

Start date: June 22, 2021
Phase: N/A
Study type: Interventional

This is a non-randomized prospective pilot intervention study to assess the feasibility of a onetime pharmacist-led video consultation for medication review and patient education among patients initiating an oral anti-cancer drug. In addition, investigator will evaluate reductions in polypharmacy, potential DDIs, and patient self-efficacy by comparing these variables for each patient before and after the video consultation.

NCT ID: NCT05298904 Active, not recruiting - Kidney Transplant Clinical Trials

Pro-active Genetic Testing in Kidney Transplant Patients

Start date: March 28, 2022
Phase:
Study type: Observational

The purpose of this study is to determine the prevalence of genetic mutations that increase the risk of cancer and other medically actionable diseases in kidney transplant patients and to assess the impact of genetic testing on subsequent surveillance for cancer.